In this first partnership of its kind in Europe, Myeloma UK and the SGC have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.
Read more (SGC website)